Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis strikes AAV capsid deal with Voyager

by Michael McCoy
March 19, 2022 | A version of this story appeared in Volume 100, Issue 10

Novartis will pay Voyager Therapeutics $54 million, plus potential future payments, for an option to license adeno-associated virus (AAV) capsids, or shells, for delivering gene therapies. Novartis markets Zolgensma, a gene therapy for spinal muscular atrophy that is delivered with AAVs. But Voyager says conventional AAVs require high doses that can be toxic. The firm says AAV capsids discovered with its Tracer platform can better target desired tissue and cell types.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.